Based on the pivotal role of the AMPK/Sirt1/eNOS network in hepatic metabolism and the promising results of this animal study, the Sild-Met-Leu combination provides a new therapeutic approach to treat NAFLD and NASH. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.